The opening bell is bearing down on us and I've got a past champ Nasdaq idea back on notice.

SmallCapFirm

Nasdaq Low Float Profile (MYNZ) Is A Past Champ Requiring Immediate Focus (Here's Why)

September 28th

SCF Readers,

The opening bell is bearing down on us and I've got a past champ Nasdaq idea back on notice.

Not only is this a past champ, it's a 2X past champ.

When it was originally brought to your attention, it made an insane move of approximately over 200% in the short term (multi-dollar mover).

Noticing it could be breakout bound once again, it was delivered to my followers' inboxes only to watch it pop another 30+% in a very little period of time.

Pair that knowledge with the fact that I delivered two profiles last week that surged 22% and 25% short term, and you'd be foolish not to get this idea on radar immediately.

Plus, with a low float providing the potential for daily volatility, multiple oversold leaning technicals signaling a possible healthy reversal could be nearing, and TipRanks reporting it to have a $25 price target, this Nasdaq profile needs full focus Wednesday.

Right now this 2X champ requires complete attention:

*Mainz Biomed B.V. (MYNZ)*

Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company's flagship product is ColoAlert, an accurate, non-invasive, and easy-to-use early detection diagnostic test for colorectal cancer.

And right now, 5 potential catalysts could provide this profile with a breakout spark near term. Here's what to know:

No. 1 - Low Float Volatility Could Be On Display Daily

No. 2 - An H.C. Wainwright $25 Price Target

No. 3 - This 2X Past Champ Oozes With Bounce/Reversal Potential

No. 4 - Key Company Highlights Provide A Bullish Future Outlook

No. 5 - Commercial Availability of ColoAlert Grows

But more on those in a second...

About MYNZ: Early Identification Of Cancer Saves Lives

Mainz BioMed – founded in Mainz, Germany and aiming to become a leading provider of easy-to-use diagnostic solutions for patients everywhere.

Developing market-ready molecular in-vitro diagnostics tests since 2010.

Their goal is to place effective solutions where they need to be… In your hands.

A Blockbuster Early Detection Test for Colorectal Cancer

Significant Impact: Colorectal cancer is the 2nd most lethal cancer in the US, but also highly preventable; with early detection providing 5-year survival rates above 90%.

Revenue Generating: ColoAlert is CE-IVD marked and is approved for sale in Europe. European sales will provide near-term revenue potential, while we prepare our entry into the US market. Process launched in 1Q2022.

U.S. Markets: We have begun the FDA process. Recent FDA guidance recommends colorectal cancer screening for everyone over the age of 45, which translates to market potential of over 52Mn tests per year.

Ease of Use: Non-invasive test, which can be taken at home, with rapid response of 92% specificity and 85% sensitivity (which is expected to be increased for the FDA product). Designed to be easier to administer than Exact Science’s ColoGuard, more accurate than FIT, and much less invasive than a colonoscopy.

Experienced Management: Seasoned and experienced management, board & advisors with particular skill sets in commercializing and monetizing medical diagnostics at some of the largest medical companies in the world.

Attractive Valuation: They believe their current valuation holds tremendous upside.

image

ColoAlert - Simple, Fast, Accurate and Non-Invasive

  • A PCR-based CRC early detection stool test
  • Non-invasive, no preparation or sedation, no time off work
  • 98% patient satisfaction – Easy product to use
  • Designed to offer affordable CRC screening solutions
image
image

Grab more key details and sources here.

-----

Mentioned above, MYNZ has 5 potential catalysts that could provide it with a near term breakout spark. Check them out:

No. 1 MYNZ Potential Catalyst - Low Float Volatility Could Be On Display Daily

According to the Yahoo Finance website, MYNZ has a low float.

The website reports this profile to have approximately 10.56Mn shares in its float.

Why is that important? It's important on one crucial level. Volatility.

Could more 2022 positive company news help provide a near term spark?

-----

No. 2 MYNZ Potential Catalyst - An H.C. Wainwright $25 Price Target

Wow. Over at TipRanks, I found this:

image

From Tuesday's closing valuation, MYNZ is displaying a ton of potential upside to this $25 target.

In fact, that's over 200+% potential upside.

Now, I'm not saying this profile is going to surge to $25 this week, but over the past 52-week period it has a high of $30.

Even a partial return to those levels would mean a major move from MYNZ from current trading areas.

-----

No. 3 MYNZ Potential Catalyst - This 2X Past Champ Oozes With Bounce/Reversal Potential

As of 12:00PM EST Tuesday, Barchart was reporting this profile to have several oversold leaning technicals.

These technicals could be signaling a healthy reversal in the near term.

Here's the definition of a "reversal" from Investopedia:

"A reversal is a change in the price direction of an asset. A reversal can occur to the upside or downside. Following an uptrend, a reversal would be to the downside. Following a downtrend, a reversal would be to the upside. Reversals are based on overall price direction and are not typically based on one or two periods/bars on a chart."

Now, here are some key technicals (as of 12:00PM EST Tuesday) that could signal KULR to be leaning oversold and on the verge of a potential reversal.

  • 9-Day Relative Strength Index: 26.68%
  • 14-Day Relative Strength Index: 31.00%

When these numbers drop down to the 30% range and lower, they can be viewed as being in oversold territory. While in this territory, they can paint the picture of a profile that is undervalued.

Keep an eye on these technicals closely.

-----

No. 4 MYNZ Potential Catalyst - Key Company Highlights Provide A Bullish Future Outlook

Mainz Biomed Reports First Half 2022 Fi-nan-cial Results

  • 127% year-over-year increase in ColoAlert revenue
  • Mid-year cash balance of $26Mn

BERKELEY, Calif. and MAINZ, Germany, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today financial results for the first half of the fiscal year ended June 30, 2022.

Key Corporate & Product Development Highlights

  • Accelerated international commercial activities for ColoAlert, the Company’s highly efficacious and easy-to-use detection test for colorectal cancer (CRC)
  • Appointed Darin Leigh, former Abbott and Luminex executive, as Chief Commercial Officer
  • Established partnership with Dante Labs to market ColoAlert in Italy and the United Arab Emirates
  • Initiated and enrolled the first patient in an international clinical study (ColoFuture) evaluating the integration of novel mRNA biomarkers into ColoAlert – potentially upgrading its technical profile to achieve “gold standard” status for CRC at-home testing
  • Received supportive feedback from the U.S. Food and Drug Administration (FDA) on ColoAlert’s pre-submission package for its U.S. pivotal clinical trial set to commence in Q4 2022
  • Achieved multiple preclinical milestones supporting the continued development of PancAlert, a potential first-in-class screening test for pancreatic cancer
  • Executed a $25.8Mn (gross) public follow-on offering
  • Expanded Strategic Advisory Board of global leaders in molecular diagnostic development and commercialization

At the outset of 2022, we established ambitious commercial and product development objectives for the year, mostly around our flagship product ColoAlert. I’m pleased to report that we achieved all of our corporate growth goals for the first half period,” commented Guido Baechler, Chief Executive Officer of Mainz Biomed. “The Company is fi-nan-cially well positioned to maintain momentum as ColoAlert continues to gain impressive commercial traction across Europe and select international territories, and as we ramp up to launch its U.S. pivotal clinical trial by the end of the year.

...

Read the full article here.

-----

No. 5 MYNZ Potential Catalyst - Commercial Availability of ColoAlert Grows

Mainz Biomed and Dante Genomics Announce Full Commercial Availability of ColoAlert in Italy and the United Arab Emirates

– ColoAlert to be marketed through Dante’s extensive database and sold via its region-specific, ecommerce websites –

BERKELEY, Calif. and MAINZ, Germany and NEW YORK, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz'' or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, and Dante Genomics, a global leader in genomics and precision medicine, announced today the formal commencement of ColoAlert’s consumer commercial program in Italy and the United Arab Emirates (UAE). ColoAlert is Mainz’s flagship product, a highly efficacious and easy to use, at-home detection test for colorectal cancer (CRC) currently being commercialized across Europe and select international markets. With the ColoAlert test CE-IVD certified and patient collection kit CE marked to the latest IVDR requirements, ColoAlert will now be marketed through Dante’s extensive database and sold via Dante’s, region-specific, ecommerce websites.

This is an important milestone for the company as it expands our global footprint while providing access to those who can benefit from our cutting-edge early detection CRC test in these additional major international territories,” commented Guido Baechler, Chief Executive Officer of Mainz Biomed. “Dante has been an exceptional partner, and we look forward to continue working closely with them as they actively market and sell ColoAlert and also as they transition from processing samples at Mainz’s in-house facility, to their own wholly-owned automated genomic sequencing laboratories in Italy (Europe) and Dubai (UAE) where they’ll offer localized service and support.

Dante Genomics is a global leader in whole genome sequencing and holds an existing database of tens of thousands of whole genomes. The company has a product development and commercial franchise focused on providing personalized preventive healthcare solutions. It achieves this by leveraging its robust databases and proprietary software platform to offer next-generation diagnostic tools direct to consumers and healthcare professionals.

From our perspective, ColoAlert represents the first true step toward personalized medicine in colorectal cancer, and we are excited to leverage our expertise in genomic data to partner with Mainz in commercializing this important diagnostic tool,” said Andrea Riposati, Chief Executive Officer of Dante Genomics. “Through our partnership with Mainz, we will drive more informed healthcare decisions and empower patients with their genomic data.

Read the full article here.

-----

MYNZ Recap - 5 Must-Know Potential Catalyst For This Nasdaq Past Champ

No. 1 - Low Float Volatility Could Be On Display Daily

No. 2 - An H.C. Wainwright $25 Price Target

No. 3 - This 2X Past Champ Oozes With Bounce/Reversal Potential

No. 4 - Key Company Highlights Provide A Bullish Future Outlook

No. 5 - Commercial Availability of ColoAlert Grows

-----

Coverage is officially reinitiated on MYNZ. When time permits, do this:

image

Get MYNZ on your radar now.

Sincerely,

Axel Adams

Editor, SCF


(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)​

StockWireNews (stockwirenews . com) is owned by SWN Media LLC, a limited liability company (SWN Media LLC has recently retained ownership of StockNewsWire LLC). Disclosure: Make sure to always do your own research and due diligence on any day and swing trade profile I bring to your attention. I am not a license d finan.cial advise r. All potential percentage gains are based on from the low to the high of day. SmallCapFirm's full disclosure is to be read and fully understood before using SmallCapFirm's website, or joining SmallCapFirm's email or text list. By viewing SmallCapFirm's website and/or reading SmallCapFirm's email or text newsletter you are agreeing to SmallCapFirm's full disclosure which can be read at: smallcapfirm.com/disclosure StockWireNews (stockwirenews . com) is owned by SWN Media LLC, a limited liability company (SWN Media LLC has recently retained ownership of StockNewsWire LLC). An owner of SWN Media LLC owns and operates smallcapfirm . com (“SCF”), owns an interest in the limited liability company that owns and operates fierceinvestor . com (“FI”), an interest in the limited liability company that owns and operates stockstreetwire . com (SSW), and an interest in the limited liability company that owns and operates nasdaqwirenews . com (NWN) . From time to time, StockWireNews, SCF, FI, SSW, and/or NWN will publicly disseminate information about a company via website, email, SMS and other points of media. Pursuant to an agreement between StockNewsWire LLC and Awareness Consulting Network LLC, StockWireNews was hired for a period beginning on 12/8/21 and ending on 12/9/21 to publicly disseminate information about (MYNZ) via Website, Email and SMS. We were paid twenty-seven thousand five hundred USD via bank wire transfer. We own zero shares of (MYNZ). Pursuant to an agreement between SWN Media LLC and TD Media LLC, SmallCapFirm (SCF) has been hired for a period beginning on 6/6/22 and ending on 6/7/22 to publicly disseminate information about (MYNZ) via Website, Email and SMS. SWN Media LLC was paid twenty-seven thousand five hundred USD via bank wire transfer. We own zero shares of (MYNZ). Pursuant to an agreement between SWN Media LLC and Awareness Consulting Network LLC, SmallCapFirm (SCF) has been hired for a period beginning on 9/27/22 and ending on 9/29/22 to publicly disseminate information about (MYNZ) via Website, Email and SMS. SWN Media LLC was paid twenty-two thousand five hundred USD via bank wire transfer. We own zero shares of (MYNZ). To date we have now been compensated a total of seventy-seven thousand five hundred USD via bank wire transfer to disseminate information about (MYNZ).